Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
3.25% $12.08
America/New_York / 26 apr 2024 @ 15:14
FUNDAMENTALS | |
---|---|
MarketCap: | 391.26 mill |
EPS: | -3.30 |
P/E: | -3.66 |
Earnings Date: | Jun 13, 2024 |
SharesOutstanding: | 32.39 mill |
Avg Daily Volume: | 0.140 mill |
RATING 2024-04-26 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.66 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.62x |
Company: PE -3.66 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.55 (-78.89%) $-9.53 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 10.65 - 13.29 ( +/- 11.05%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-05-10 | Oxford Science Enterprises Plc | Buy | 879 970 | Common Stock |
2024-03-01 | Svenstrup Niels | Buy | 83 000 | Stock Option (Right to Buy) |
2024-03-01 | Mcarthur James G | Buy | 300 000 | Stock Option (Right to Buy) |
2024-03-01 | Donnelly Noel | Buy | 144 000 | Stock Option (Right to Buy) |
2024-03-01 | Mellion Michelle L | Buy | 83 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
86.20 |
Last 93 transactions |
Buy: 15 622 342 | Sell: 5 738 999 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $12.08 (3.25% ) |
Volume | 0.0247 mill |
Avg. Vol. | 0.140 mill |
% of Avg. Vol | 17.64 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.63 | N/A | Active |
---|
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.